Catherine Sims, MD DrCassySims
3 years 11 months ago
Reproductive concerns of adolescent patients with rheumatic disease
Abstract #129 #ACR22 @RheumNow
🤰Worried about effects of dx and meds on fertility and pregnancy
💊Concerns about which birth control to use
🩸Effects of dx. on menstruation
Richard Conway RichardPAConway
3 years 11 months ago
Kimbrough et al. Comorbidities assoc serious infection in RA. Many! 26/55 comorbidities assoc serious infection. Number of comorbidities also assoc HR 1.16 (1.13-1.19) @RheumNow #ACR22 Abstr#1950 https://t.co/gnIlaJ037B https://t.co/6SR2Ej584w
Aurelie Najm AurelieRheumo
3 years 11 months ago
RA asso w/ higher risk of lung cancer aHR 1.53, also in non-smokers aHR 1.66 🚬
Now this risk increases even more in pts w/ RA-ILD 🫁
aHR 3.06
No adjustment on occupation or non tobacco inhaled toxic exposure
https://t.co/41ibPD6S3b
Abs#1647 #ACR22 @RheumNow https://t.co/LNw792MYV0
Dr. John Cush RheumNow
3 years 11 months ago
Does Evusheld shield people living with rheumatic diseases? #ACR22
https://t.co/IutdoFxJUx https://t.co/FuKZEtpImm
Olga Petryna DrPetryna
3 years 11 months ago
#L02 #acr22 @rheumnow Bimekizumab ph3 in PsA: meaningful clinical improvement, improved mTSS, no new safety signals. Wk 52 ACR50: 53.0% PBO/BKZ, 54.5% BKZ, 50.0% ADA; MDA 53.7% PBO/BKZ, 55.0% BKZ, 52.9% ADA . mTSS change from baseline ≤0.5): 87.3% PBO/BKZ, 89.3% BKZ, 94.1% ADA https://t.co/NYRrPUBjt1
Richard Conway RichardPAConway
3 years 11 months ago
Yazici et al. IA Lorecivivint in Knee OA. 56 week DB-RCT of single injection at time 0. Didn't work. Not for primary endpoint (Pain NRS) or any PRO. @RheumNow #ACR22 Abstr#1639 https://t.co/66KyJW1zVz
David Liew drdavidliew
3 years 11 months ago
Ultrasound and MRI have taught us a lot about PMR, but it's the power of PET/CT which illustrated the specific pathology of PMR in full color vision.
@drceowen #ACR22 @RheumNow https://t.co/N8hVjqpVwe
Eric Dein ericdeinmd
3 years 11 months ago
14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴
Initial Fracture Risk Assessment - by age - remember: no FRAX scores <40 yo
Fracture re-assessments every 1-2 years with repeat BMD and risk stratifications
@RheumNow https://t.co/QlCVM1lDb0
Aurelie Najm AurelieRheumo
3 years 11 months ago
BE OPTIMAL: BKZ in PsA Phase 3 RCT
Data at 52 wks 700+ completed study
ACR50: 53% PBO/BKZ, 54% BKZ, 50% ADA
PASI 100 65% PBO/BKZ, 61% BKZ, 48% ADA
No Rx progression 87% PBO/BKZ, 89% BKZ, 94% ADA
Candida infections 7% BKZ, 0.7% ADA
https://t.co/MMjN1Aa3qf
Abs#L02 #ACR22 @Rheumnow https://t.co/keF0QOZMwA
TheDaoIndex KDAO2011
3 years 11 months ago
Dr. B Humphrey #ACR22 #Osteoporosis Guidelines:
in patients under 40 yo, you cannot calculate #FRAX score, assess BMD and in children get also thoracolumbar xrays. Get repeat testing every 1-2 years #ACR22 @rheumnow https://t.co/CgsvzGKYuV
Janet Pope Janetbirdope
3 years 11 months ago
Get the skinny on Bimmy! Gotta learn this name #Bimekizumab in bio naive PsA N=852 Bimmy=IL17 A & F inhibitor Great data on skin & joints. Where will it fit in as we have other IL17Ai’s is IL17F giving added value? #ACR22 #ACRBest @RheumNow https://t.co/wNAzTaLhsM
Aurelie Najm AurelieRheumo
3 years 11 months ago
800+ women w/ IMID & 1700+ ctrl w/ 6 yrs follow-up
All GC users < BMD levels
-4.2% > 2.5mg/d
-2.7% <2.5mg/d
Crude FX rate 4.8/100PY GC >= 5mg/d, 2.5/100PY GC < 2.5mg/d
🦴Fx incidence > IMID vs. Ctrls
GC use >= 5mg/d x2 risk of Fx
https://t.co/6sj77PwyYQ
Abs#L01 #ACR22 @Rheumnow https://t.co/OZhfuh0Jrm
There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease. Are the differences only cultural or are there important clinical differences in the disease presentation, organ involvement and complications that physicians should be aware of?
